January 16, 2024
|
Biora Therapeutics Provides Outlook for 2024
|
January 8, 2024
|
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
|
January 2, 2024
|
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
|
December 19, 2023
|
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
|
December 18, 2023
|
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
|
December 11, 2023
|
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
|
November 30, 2023
|
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
|
November 13, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|
November 6, 2023
|
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
|
October 30, 2023
|
Biora Therapeutics Submits Updated IND Application for BT-600
|